RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge

Stay ahead of the latest advancements in rheumatology with this in-depth RhAPPcast episode exploring TYK2 inhibition and its expanding role in immune-mediated diseases. Hosted by Amanda Mixon, PA-C, this episode features expert insights from Danielle Gatti-Palumbo, PharmD, and Jennifer Mylod, DNP, as they break down the science behind TYK2 signaling within the JAK-STAT pathway and its clinical relevance in conditions like psoriatic arthritis, systemic lupus erythematosus (SLE), and Sjögren’s syndrome.Learn how TYK2 inhibitors—such as deucravacitinib—are reshaping treatment strategies by targeting key cytokines like IL-12, IL-23, and type 1 interferons, offering a potentially effective oral alternative with a differentiated safety profile compared to traditional JAK inhibitors. The discussion highlights pivotal clinical trials including POETYK PSO-1, POETYK PSO-2, and emerging phase 3 data in psoriatic arthritis, as well as promising findings from the PAISLEY trial in lupus. Additionally, the episode explores the unmet need in Sjögren’s syndrome and how evolving trial designs and outcome measures may pave the way for future targeted therapies.Whether you're a rheumatology provider, advanced practice provider (APP), or healthcare professional interested in autoimmune disease management, this episode delivers key clinical insights, trial data, and future considerations shaping the next wave of immunomodulatory therapies. For more rheumatology education, check out the RhAPP Content Rheum or download the RhAPP ACE app.